Targets › AKT1
11 programs from 10 companies in 56 trials: 24 Phase 2, 20 Phase 1, 12 Phase 3; Oncology, Other, Gastroenterology; next expected readout Nov 2026.
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. (UniProt, P31749)
Open in Phaseline: the race on AKT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Capivasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer … | Nov 2026 |
| Laekna | Afuresertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Breast Cancer | Dec 2026 |
| Roche | Ipatasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer … | Feb 2028 |
| Zhejiang Haichang Biotech | WGI-0301 Antisense oligonucleotide complementary to Akt-1 mRNA | AKT1 | Phase 2 | Advanced Hepatocellular Carcinoma (HCC) | Dec 2026 |
| National Cancer Institute (NCI) | Uprosertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | Recurrent Uveal Melanoma | Jul 2027 |
| VA Office of Research and Development | Itraconazole Cytochrome P450 51 inhibitor | SMO, AKT1, VEGFA | Phase 2 | Esophageal Adenocarcinoma | Apr 2029 |
| Merck & Co. (MSD) | Miransertib (MK-7075) Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus Syndrome | Feb 2030 |
| QuantumLeap Healthcare Collaborative | MK-2206 Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | Breast Neoplasms | Dec 2030 |
| Alterome Therapeutics | ALTA2618 AKT1 E17K inhibitor | AKT1 | Phase 1 | Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Mk-2206 (MK2206) Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 1 | Advanced Malignant Solid Neoplasm | Mar 2027 |
| Atavistik Bio | ATV-1601 AKT1 E17K inhibitor | AKT1 | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT); Advanced Solid Tumors | Dec 2027 |
Breast Cancer (5) Metastatic Breast Cancer (4) Advanced Lymphoma (3) Locally Advanced (Inoperable) or Metastatic Breast Cancer (2) Prostate Cancer (2) Triple Negative Breast Neoplasms (2) Cancer (2) Hormone-Sensitive Prostate Cancer (1) Locally Advanced or Metastatic Breast Cancer (1) Moderate Hepatic Impairment (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) CCCA Assessed by Ki67 Drop Below <2.7% From Baseline (1)
small molecule (7), mixed (4)
National Cancer Institute (NCI) (2) AstraZeneca (1) Merck & Co. (MSD) (1) Roche (1) Laekna (1) Alterome Therapeutics (1) QuantumLeap Healthcare Collaborative (1) Zhejiang Haichang Biotech (1) Atavistik Bio (1) VA Office of Research and Development (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.